<strong>Objective: </strong><span style="font-family:""><span style="font-family:Verdana;">To investigate the clinical effects of</span><a name="_Hlk26140...<strong>Objective: </strong><span style="font-family:""><span style="font-family:Verdana;">To investigate the clinical effects of</span><a name="_Hlk26140736"></a><span style="font-family:Verdana;"> recombinant human interleukin-2 (rhIL-2) combined with </span><a name="_Hlk26140744"></a><span style="font-family:Verdana;">Zhenqi Fuzheng and Baofukang on cervical intraepithelial neoplasia II (CINII) combined with human papilloma virus infection. </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:Verdana;">There were 593 patients diagnosed with CINII with HPV infection, including 296 in the control group and 297 in the experimental group. The control group was given only Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine. The experimental group was treated with rhIL-2 injection in addition to Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine which is treated for 3 months. After 3 months, Thinprep cytologic test (TCT), human papilloma virus (HPV) quantitative examination and colposcopy biopsy were reviewed. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> After 3 months of treatment, the negative conversion rate and total effective rate of HPV in the control group were 58.11% and 70.95% respectively, and the negative conversion rate and total effective rate of the experimental group were 79.46% and 90.57% respectively. There was significant difference between the two groups (p = 0.000). The curative rate of cervical lesions was significantly higher in the test group than in the control group, 89.56%, 68.91%, respectively. The statistical difference between the two groups is significant (p = 0.000). </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> It has an essential clinical value that HPV infection patients and cervical intraepithelial neoplasia II associated with </span><a name="_Hlk47768779"></a><span style="font-family:Verdana;">HPV infection patients are treated by rhIL-2 combined with Zhenqifuzheng and Baofukang, </span><a name="_Hlk47805707"></a><span style="font-family:Verdana;">which is safe, effective, non-invasive, reusable advantages. However, the long-term efficacy and side effects need to be further studied.</span></span>展开更多
文摘<strong>Objective: </strong><span style="font-family:""><span style="font-family:Verdana;">To investigate the clinical effects of</span><a name="_Hlk26140736"></a><span style="font-family:Verdana;"> recombinant human interleukin-2 (rhIL-2) combined with </span><a name="_Hlk26140744"></a><span style="font-family:Verdana;">Zhenqi Fuzheng and Baofukang on cervical intraepithelial neoplasia II (CINII) combined with human papilloma virus infection. </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:Verdana;">There were 593 patients diagnosed with CINII with HPV infection, including 296 in the control group and 297 in the experimental group. The control group was given only Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine. The experimental group was treated with rhIL-2 injection in addition to Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine which is treated for 3 months. After 3 months, Thinprep cytologic test (TCT), human papilloma virus (HPV) quantitative examination and colposcopy biopsy were reviewed. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> After 3 months of treatment, the negative conversion rate and total effective rate of HPV in the control group were 58.11% and 70.95% respectively, and the negative conversion rate and total effective rate of the experimental group were 79.46% and 90.57% respectively. There was significant difference between the two groups (p = 0.000). The curative rate of cervical lesions was significantly higher in the test group than in the control group, 89.56%, 68.91%, respectively. The statistical difference between the two groups is significant (p = 0.000). </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> It has an essential clinical value that HPV infection patients and cervical intraepithelial neoplasia II associated with </span><a name="_Hlk47768779"></a><span style="font-family:Verdana;">HPV infection patients are treated by rhIL-2 combined with Zhenqifuzheng and Baofukang, </span><a name="_Hlk47805707"></a><span style="font-family:Verdana;">which is safe, effective, non-invasive, reusable advantages. However, the long-term efficacy and side effects need to be further studied.</span></span>
